Tag Archives: IFN

New Personalized Medicine Increases Survival in Melanoma Patients

Posted on April 3, 2011 by wngai

Metastatic melanoma is the deadliest and most aggressive from of skin cancer. A person with metastatic melanoma typically has a short life expectancy that is measured in months. The mainstay treatments for metastatic melanoma are dacarbazine (DTIC), interleukin-2 (IL-2) and … Continue reading →

Posted in Cancer, Melanoma | Tagged BRAF V600 mutation, dacarbazine, DTIC, Genentech, IFN, IL-2, interferon, interleukin-2, Melanoma, Metastatic melanoma, Patient Access Program, progression-free survival, RG7204, Roche, Survival | Comments Off